摘要
目的观察芪苈强心胶囊对扩张型心肌病患者心功能及血管内皮功能的影响。方法选择2014年1月—2017年6月河北以岭医院心内科诊治扩张型心肌病患者556例作为研究对象,采用随机、双盲、安慰剂对照的方法,556例受试者随机分为试验组和对照组,每组278例。以标准化心力衰竭治疗为基础治疗,本基础治疗基础上试验组用芪苈强心胶囊治疗,对照组采用安慰剂治疗,疗程均为12个月。比较2组受试者左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、右室收缩末期内径(LVESD)、左室短轴缩短率(FS)、一氧化氮(NO)含量、内皮素-1(ET-1)含量、可溶性血管内皮黏附因子(SICAM-1)含量及反应性充血后内径变化率。结果与对照组比较,试验组LVEF、FS明显提高[(45.52±9.64)%vs.(43.38±8.17)%),t=2.640,P=0.001;(26.34±3.95)vs.(23.06±4.24)%,t=8.811,P=0.000],LVEDD、LVESD明显降低[(68.12±9.06)mm vs.(69.89±8.06)mm,t=2.266,P=0.024;(38.12±2.95)mm vs.(41.35±3.32)mm,t=11.328,P=0.000];试验组NO含量明显升高[(46.86±13.56)μmol/L vs.(44.23±12.58)μmol/L,t=2.209,P=0.000),ET-1及SICAM-1含量明显降低[(37.03±15.39)ng/L vs.(40.25±16.89)ng/L,t=2.194,P=0.029,(238.96±68.93)ng/L vs.(258.13±69.15)ng/L,t=3.053,P=0.002],反应性充血后内径变化率变化值明显增大[(11.39±2.51)%vs.(10.53±2.05)%,t=4.115,P=0.000]。结论芪苈强心胶囊治疗扩张型心肌病安全有效,其作用机制可能是通过调节血管活性物质含量从而改善血管内皮功能实现的。
Objective To evaluate the influence of Qiliqiangxin capsule to the heart function and vascular endothelial function of the patients with dilated cardiomyopathy.Methods Taking the trial methods of random,double-blinded and placebo controlled,556 subjects who were dilated cardiomyopathy patients in the department of cardiology of hebei Yiling Hospital from Jan.2014 to Jun.2016 were divided into treatment group and control group randomly,and each group was 278.Based on the standardized heart failure treatment,the subjects in the treatment group were treated with Qiliqiangxin capsule,and the control group was taken Perindopril and placebo.The courses were all 12 months,then observed the two groups’change value of LVEF,LVEDD,LVESD,FS,NO content,ET-1 content,SICAM-1 content,and the rate of change of internal diameter after reactivity.Results To compare with the control group,the LVEF and FS was enhanced[(45.52±9.64)%vs.(43.38±8.17)%,(26.34±3.95)vs.(23.06±4.24)%,t=2.640,P=0.001,t=8.811,P=0.000],LVEDD and LVESD reduce obviously in the treatment group[(68.12±9.06)mm vs.(69.29±8.06)mm,(38.12±2.95)mm vs.(41.35±3.32)mm,t=2.266,P=0.024,t=11.328,P=0.000],which declared that the heart function of the treatment group improved more obviously.The NO content enhanced ovbiously[(46.86±13.56)μmol/L vs.(44.23±12.58)μmol/L,t=2.209,P=0.000],ET-1 content and SICAM-1 content lower ovbiously[(37.03±15.39)ng/L vs.(40.25±16.89)ng/L,t=2.194,P=0.029,(238.96±68.93)ng/L vs.(258.13±69.15)ng/L,t=3.053,P=0.002],and the rate of change of internal diameter after reactivity[(11.39±2.51)%vs.(10.53±2.05)%,t=4.115,P=0.000]enlarged obviously compared the control group.The difference of all above results between the two groups had statistical?significance(P<0.05).Conclusion It was safety and efficiency that Qiliqiangxin capsule treated dilated cardiomyopathy,and the mode of action maybe improve the function of vascular endothelial by adjustingthe content of the active material of blood vessels.
作者
吴相君
赵保礼
韩硕龙
张喜芬
WU Xiangjun;ZHAO Baoli;HAN Shuolong;ZHANG Xifen(Hebei Yiling Medical Research Institute,Iuobing Research and Innovation of TCM of National Key Laboratoriy,the Key Research Office of SATCM,Shijiazhuang 050035,China)
出处
《疑难病杂志》
CAS
2018年第4期329-333,共5页
Chinese Journal of Difficult and Complicated Cases
关键词
血管内皮
扩张型心肌病
芪苈强心胶囊
临床试验
Vascular endothelial
Dilated cardiomyopathy
Qiliqiangxin capsule
Clinical study
